Cassava skyrockets after SEC clears data manipulation case

The Securities and Exchange Commission has reportedly authorized an investigation into Cassava Sciences (SAVA), which sent SAVA shares to a seven-month high on Thursday.


Afternoon is traded today’s stock marketSAVA shares jumped 32.1% to close at 49.70.

Last November, the SEC launched an investigation into Cassava’s simufilam research. The scientists, who also held short positions in SAVA stock, claimed cassava manipulated images used in testing the experimental Alzheimer’s treatment.

On Thursday, Seeking Alpha published a document showing that the SEC had reached a “five-page case closure recommendation.”

The agency declined to release the full decision, citing attorney privilege. Representatives for Cassava did not immediately return a request for comment.

SAVA Stock: Stabilization of a key protein

Allegations of data manipulation have weighed on SAVA’s stock since last year. The scientists at the center of the allegations also asked the Food and Drug Administration to halt research on cassava. But the agency refused to do so.

According to cassava, simufilam works by stabilizing an abnormal protein in the brain.

Thursday’s news sent SAVA shares to their highest point since February. Shares continued the recent surge well above theirs key moving averagesAccording to

SAVA shares also have a strong Relative strength assessment of 84, an indicator of 12-month performance. The best performing stocks have an RS rating of at least 80, according to IBD Digital.

Follow Alison Gatlin on Twitter at @IBD_AGatlin.


Here are the Novavax vaccination numbers in the US – and they’re grim

Eli Lilly’s “transformational” drug that could reach $25 billion in annual sales

Find the best long-term investments with IBD’s long-term leaders

Stocks to buy and watch: Top IPOs, large and small caps, growth stocks

Follow pre-market and post-open action with IBD experts

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *